Important note: Information in this article was accurate in 2003. The state of the art may have changed since the publication date.
![]()
Reuters NewMedia - Wednesday November 12, 2003
Gordon Bell
Finance Minister Trevor Manuel said the government would spend more than $1.7 billion over the next three years, with $270 million earmarked to launch the roll-out of a national anti-retroviral (ARV) treatment program.
"Starting next year and the two successive years the amounts have been increased, I think we are talking about a total of 12 billion rand ($1.73 billion)," Manuel told reporters Wednesday prior to unveiling the medium term budget in Parliament.
This compares with an estimated $480 million spent between 2001/02 financial year to the current 2003/04 year. Treasury officials said the funds allocated for the roll-out of the life-prolonging ARV drugs was new money.
"This is good news. It's a positive signal which does suggest to me that the government is going to spend almost as much as it does on black economic empowerment. It's become a government priority," said Professor Tom Lodge of the University of Witwatersrand.
South Africa has the highest HIV/AIDS caseload in the world -- an estimated 5.3 million, equivalent to more than 12 percent of the population of 45 million.
But health activists have accused the government of dragging its feet, with President Thabo Mbeki and Health Minister Manto Tshabalala-Msimang criticized for failing to grasp how serious the crisis is.
Under growing local and international pressure to respond more aggressively and avert possible long-term economic decline, President Thabo Mbeki's government approved a universal ARV roll-out in August in principle and ordered health officials to finalize an operational plan.
Wednesday, the cabinet said it had noted that the Treasury had allocated the resources required to implement the treatment program.
A cabinet meeting scheduled for next week is now expected to give the final go-ahead for the operational plan.
"Planning for implementation of a national anti-retroviral program is at an advanced stage, and procurement teams are exploring mechanisms to reduce the unit costs of treatment further," the National Treasury said.
031112
RE031113
Copyright © 2003 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Contact Reuters.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .